<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447458</url>
  </required_header>
  <id_info>
    <org_study_id>MLN3126_102</org_study_id>
    <secondary_id>U1111-1163-1717</secondary_id>
    <nct_id>NCT02447458</nct_id>
  </id_info>
  <brief_title>MLN3126 Single Rising Dose Study</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of
      MLN3126 when administered as a single dose of tablets at escalating dose levels in healthy
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug tested in this study is called MLN3126. The study evaluated the safety,
      tolerability, pharmacokinetics (PK), pharmacodynamics and the potential effect of food on the
      PK of MLN3126 and its M-I metabolite following single oral dose administrations.

      This study planned to enroll approximately 48 healthy participants, who were to be enrolled
      in 1 of the 6 dose cohorts or matching placebo in an ascending fashion. Participants were
      randomly assigned to MLN3126 or placebo within each cohort- which remained undisclosed to the
      participant and study doctor during the study (unless there was an urgent medical need):

        -  Cohort 1 - MLN3126 300 mg or matching placebo

        -  Cohort 2 - MLN3126 600 mg or matching placebo

        -  Cohort 3 - MLN3126 1000 mg or matching placebo

        -  Cohort 3 - MLN3126 1000 mg or matching placebo (fed regimen)

        -  Cohort 4 - MLN3126 1500 mg or matching placebo

        -  Cohort 5 - MLN3126 2000 mg or matching placebo

        -  Cohort 6 - Did not taken place due to termination of the study

      All participants were asked to take the required tablets at the same time throughout the
      study.

      This single-centre trial was conducted in The United States. Participants were confined to
      the clinic for 5 days, and were contacted by telephone on day 14 (±2days) for a follow-up
      assessment.

      This study was terminated after completion of Cohort 5 due to findings of study site
      non-compliance to Good Clinical Practice (GCP) regarding study documentation. There were no
      safety concerns.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Site non-compliance to GCP (No safety concerns. See detailed description)
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experience At Least One Treatment-Emergent Adverse Event (TEAE) Post-Dose</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Clinical Laboratory Results Post-Dose</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Clinical safety laboratory tests included clinical chemistry, hematology and urinalysis. The percentage of participants with any markedly abnormal laboratory finding during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Vital Signs Post-Dose</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Vital signs included oral body temperature measurement, blood pressure, respiration rate, and pulse rate [beats per minute (bpm) or heart rate]. The percentage of participant with markedly abnormal vital signs findings during the study. OBP=Orthostatic Blood Pressure. All OBP measurements were standing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Post-Dose</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>A standard 12-lead ECG was performed. The percentage of participants with markedly abnormal electrocardiogram (ECG) findings during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Plasma Concentration of MLN3126 and Metabolite M-I</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Maximum Plasma Concentration of MLN3126 and Metabolite M-I</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Tmax is the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to the Last Quantifiable Concentration</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to Infinity</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>AUC(0-inf) is measure of area under the curve from time 0 to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Oral Clearance of MLN3126</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>CL/F is apparent clearance of the drug from the plasma, after extravascular administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T ½: Half-life of MLN3126 and Metabolite M-I</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae (0-96): Total Amount of MLN3126 and Metabolite M-I Excreted in the Urine</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Ae (0-96) is the total amount of drug excreted in urine from time 0 to time 96 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe: Fraction of MLN3126 Excreted in the Urine</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Fe is the Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) of MLN3126 and Metabolite M-I</measure>
    <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
    <description>Renal clearance was calculated as CLr=Ae(0-96)/AUC (0-96).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: MLN3126 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: MLN3126 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: MLN3126 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: MLN3126 1500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN3126 1500 mg administered orally as tablets, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: MLN3126 2000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN3126 2000 mg tablets, orally, fasting, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Did not take place due to termination of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Cohort 1-6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching MLN3126 tablets, orally, once on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN3126</intervention_name>
    <description>MLN3126 tablets</description>
    <arm_group_label>Cohort 1: MLN3126 300 mg</arm_group_label>
    <arm_group_label>Cohort 2: MLN3126 600 mg</arm_group_label>
    <arm_group_label>Cohort 3: MLN3126 1000 mg</arm_group_label>
    <arm_group_label>Cohort 4: MLN3126 1500 mg</arm_group_label>
    <arm_group_label>Cohort 5: MLN3126 2000 mg</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN3126 Placebo</intervention_name>
    <description>MLN3126 placebo-matching tablets</description>
    <arm_group_label>Placebo: Cohort 1-6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant was capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signed and dated a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Is a male or female adult, aged 18 to 55 years, inclusive, at the time of informed
             consent and study drug dosing.

          4. Is a healthy adult male or female subject as evidenced by their medical history,
             complete physical examination, vital signs, ECG, and safety laboratory evaluations.

          5. Weighed at least 45 kg (99 lbs) and had a body mass index (BMI) between 18 and 30.0
             kg/m2 inclusive at Screening.

          6. A male participant who was nonsterilized and sexually active with a female partner of
             childbearing potential agreed to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose. In
             addition, participants were advised not to donate sperm during this period.

          7. A female participant of childbearing potential who was sexually active with a
             nonsterilized male partner agreed to use routinely adequate contraception from signing
             of informed consent throughout the duration of the study to their next postconfinement
             menstruation. In addition participants were advised not to donate ova during this
             period.

        Exclusion Criteria:

        Any participant who meets any of the following criteria will not qualify for entry into the
        study:

          1. Has received any investigational compound within 30 days prior to the first dose of
             study medication.

          2. Is an immediate family member, study site employee, or in a dependent relationship
             with a study site employee who is involved in the conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          3. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, GI, or endocrine disease or other abnormality, which may
             impact the ability of the participant to participate or potentially confound the study
             results.

          4. Has a known hypersensitivity to any component of the formulation of MLN3126.

          5. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).

          6. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse (defined as 4 alcoholic beverages per day) within 1 year prior to the Screening
             visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.

          7. Has taken any excluded medication, supplements, or food products listed in the
             Excluded Medications and Dietary Products section of the protocol.

          8. If female, the participant is pregnant or lactating or intending to become pregnant,
             or intending to donate ova, before or during, the study; including the timeframe to
             participant's next postconfinement menstruation after participating in this study.

          9. If male, the participant intends to donate sperm during the course of this study or
             for 12 weeks thereafter.

         10. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding
             in the participant's medical history, physical examination, or safety laboratory tests
             giving reasonable suspicion of a disease that would contra indicate taking MLN3126 or
             a similar drug in the same class, or that might interfere with the conduct of the
             study. This includes, but is not limited to, peptic ulcer disease, seizure disorders,
             and cardiac arrhythmias.

         11. Has current or recent (within 6 months) GI disease that would be expected to influence
             the absorption of drugs (ie, a history of malabsorption, any surgical intervention
             known to impact absorption [eg, bariatric surgery or bowel resection], esophageal
             reflux, peptic ulcer disease, erosive esophagitis or frequent [more than once per
             week] occurrence of heartburn).

         12. Has a history of cancer or other malignancy, except basal cell carcinoma that has been
             in remission for at least 5 years prior to Day 1.

         13. Has a positive test result for hepatitis B surface antigen, antibody to hepatitis C
             virus, at Screening or a known history of human immunodeficiency virus infection.

         14. Has used nicotine-containing products (this includes, but is not limited to,
             cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28
             days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day
             -1).

         15. Has poor peripheral venous access.

         16. Has donated or lost 450 mL or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days prior to Day
             1.

         17. Has a Screening or Check-in (Day -1) abnormal (clinically significant) ECG. Entry of
             any subject with an abnormal (not clinically significant) ECG must be approved, and
             documented by signature by the principal investigator or medically qualified
             subinvestigator.

         18. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a
             clinically significant underlying disease or participant with the following laboratory
             abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
             &gt;1.5×ULN.

         19. Has QT interval with Fridericia correction method (QTcF) &gt;430 ms for men and &gt;450 ms
             for women or PR outside the range of 120 to 220 ms confirmed upon repeat testing
             within a maximum of 5 minutes, at the Screening Visit or Check-in (Day -1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>July 7, 2015</results_first_submitted>
  <results_first_submitted_qc>July 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2015</results_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 19 August 2013 (first participant signed informed consent form) to 05 February 2014.</recruitment_details>
      <pre_assignment_details>Healthy volunteers were enrolled in 1 of 5 MLN3126 ascending dose treatment groups: once a day 300 mg, 600 mg, 1000 mg under fed or fasting conditions,1500 mg or 2000 mg OR once a day placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MLN3126 300 mg</title>
          <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MLN3126 600 mg</title>
          <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MLN3126 1000 mg</title>
          <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MLN3126 1500 mg</title>
          <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MLN3126 2000 mg</title>
          <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MLN3126 300 mg</title>
          <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>MLN3126 600 mg</title>
          <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MLN3126 1000 mg</title>
          <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MLN3126 1500 mg</title>
          <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MLN3126 2000 mg</title>
          <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="10.43"/>
                    <measurement group_id="B2" value="30.3" spread="6.50"/>
                    <measurement group_id="B3" value="41.2" spread="10.42"/>
                    <measurement group_id="B4" value="32.3" spread="11.78"/>
                    <measurement group_id="B5" value="30.0" spread="8.39"/>
                    <measurement group_id="B6" value="32.8" spread="6.32"/>
                    <measurement group_id="B7" value="33.7" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.8" spread="10.64"/>
                    <measurement group_id="B2" value="172.3" spread="5.47"/>
                    <measurement group_id="B3" value="174.7" spread="10.42"/>
                    <measurement group_id="B4" value="169.8" spread="5.71"/>
                    <measurement group_id="B5" value="173.3" spread="6.09"/>
                    <measurement group_id="B6" value="174.9" spread="13.08"/>
                    <measurement group_id="B7" value="172.9" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.00" spread="12.900"/>
                    <measurement group_id="B2" value="81.98" spread="8.538"/>
                    <measurement group_id="B3" value="83.67" spread="15.871"/>
                    <measurement group_id="B4" value="72.22" spread="7.165"/>
                    <measurement group_id="B5" value="75.87" spread="10.016"/>
                    <measurement group_id="B6" value="82.58" spread="7.420"/>
                    <measurement group_id="B7" value="79.44" spread="10.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.65" spread="2.643"/>
                    <measurement group_id="B2" value="27.56" spread="2.127"/>
                    <measurement group_id="B3" value="27.18" spread="2.293"/>
                    <measurement group_id="B4" value="25.01" spread="1.811"/>
                    <measurement group_id="B5" value="25.16" spread="2.329"/>
                    <measurement group_id="B6" value="27.22" spread="3.251"/>
                    <measurement group_id="B7" value="26.54" spread="2.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experience At Least One Treatment-Emergent Adverse Event (TEAE) Post-Dose</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>Placebo matching MLN3126 tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experience At Least One Treatment-Emergent Adverse Event (TEAE) Post-Dose</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Clinical Laboratory Results Post-Dose</title>
        <description>Clinical safety laboratory tests included clinical chemistry, hematology and urinalysis. The percentage of participants with any markedly abnormal laboratory finding during the study.</description>
        <time_frame>Up to Day 16</time_frame>
        <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>Placebo matching MLN3126 tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Clinical Laboratory Results Post-Dose</title>
          <description>Clinical safety laboratory tests included clinical chemistry, hematology and urinalysis. The percentage of participants with any markedly abnormal laboratory finding during the study.</description>
          <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Vital Signs Post-Dose</title>
        <description>Vital signs included oral body temperature measurement, blood pressure, respiration rate, and pulse rate [beats per minute (bpm) or heart rate]. The percentage of participant with markedly abnormal vital signs findings during the study. OBP=Orthostatic Blood Pressure. All OBP measurements were standing.</description>
        <time_frame>Up to Day 16</time_frame>
        <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>Placebo matching MLN3126 tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Vital Signs Post-Dose</title>
          <description>Vital signs included oral body temperature measurement, blood pressure, respiration rate, and pulse rate [beats per minute (bpm) or heart rate]. The percentage of participant with markedly abnormal vital signs findings during the study. OBP=Orthostatic Blood Pressure. All OBP measurements were standing.</description>
          <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse - supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="40.0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse - standing 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse - standing 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood pressure (BP) - supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood pressure - standing 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood pressure - standing 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - standing 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="30.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - standing 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OBP systolic - 1 minutes (Decrease of &gt;40 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OBP systolic - 3 minutes (Decrease of &gt;40 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OBP diastolic - 1 minutes (Decrease &gt;20 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="40.0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OBP diastolic - 3 minutes (Decrease &gt;20 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Post-Dose</title>
        <description>A standard 12-lead ECG was performed. The percentage of participants with markedly abnormal electrocardiogram (ECG) findings during the study.</description>
        <time_frame>Up to Day 16</time_frame>
        <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
            <description>Placebo matching MLN3126 tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Post-Dose</title>
          <description>A standard 12-lead ECG was performed. The percentage of participants with markedly abnormal electrocardiogram (ECG) findings during the study.</description>
          <population>Safety population included all enrolled participants who received at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="10.0"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10.0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc - Fredericia's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Plasma Concentration of MLN3126 and Metabolite M-I</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Plasma Concentration of MLN3126 and Metabolite M-I</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic (PK) analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2466.00" spread="387.208"/>
                    <measurement group_id="O2" value="3605.00" spread="920.885"/>
                    <measurement group_id="O3" value="4061.67" spread="1192.299"/>
                    <measurement group_id="O4" value="5490.00" spread="1110.531"/>
                    <measurement group_id="O5" value="8200.00" spread="1937.431"/>
                    <measurement group_id="O6" value="9444.00" spread="1929.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.26" spread="44.940"/>
                    <measurement group_id="O2" value="238.17" spread="101.275"/>
                    <measurement group_id="O3" value="278.17" spread="176.552"/>
                    <measurement group_id="O4" value="374.00" spread="78.908"/>
                    <measurement group_id="O5" value="424.83" spread="131.574"/>
                    <measurement group_id="O6" value="684.40" spread="556.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Maximum Plasma Concentration of MLN3126 and Metabolite M-I</title>
        <description>Tmax is the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Maximum Plasma Concentration of MLN3126 and Metabolite M-I</title>
          <description>Tmax is the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.884" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.00" spread="0.894" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.14" spread="0.902" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.50" spread="2.345" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="3.01" spread="0.752" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="4.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="4.00" upper_limit="10.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="8.00" lower_limit="6.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to the Last Quantifiable Concentration</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to the Last Quantifiable Concentration</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41480.14" spread="7541.025"/>
                    <measurement group_id="O2" value="63117.71" spread="26292.596"/>
                    <measurement group_id="O3" value="73474.61" spread="29655.501"/>
                    <measurement group_id="O4" value="108475.58" spread="20425.152"/>
                    <measurement group_id="O5" value="133029.91" spread="44849.002"/>
                    <measurement group_id="O6" value="248462.35" spread="72106.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1961.73" spread="1106.451"/>
                    <measurement group_id="O2" value="4096.06" spread="2261.405"/>
                    <measurement group_id="O3" value="5550.19" spread="5139.476"/>
                    <measurement group_id="O4" value="6724.92" spread="2067.765"/>
                    <measurement group_id="O5" value="6110.64" spread="1936.969"/>
                    <measurement group_id="O6" value="11989.43" spread="10546.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to Infinity</title>
        <description>AUC(0-inf) is measure of area under the curve from time 0 to infinity.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to Infinity</title>
          <description>AUC(0-inf) is measure of area under the curve from time 0 to infinity.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41765.17" spread="7549.827"/>
                    <measurement group_id="O2" value="63508.18" spread="26520.426"/>
                    <measurement group_id="O3" value="78964.45" spread="40182.582"/>
                    <measurement group_id="O4" value="110437.12" spread="20911.078"/>
                    <measurement group_id="O5" value="134119.22" spread="45470.528"/>
                    <measurement group_id="O6" value="250789.67" spread="73569.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1993.65" spread="1099.291"/>
                    <measurement group_id="O2" value="4132.89" spread="2266.377"/>
                    <measurement group_id="O3" value="6668.14" spread="7725.447"/>
                    <measurement group_id="O4" value="6949.52" spread="2129.918"/>
                    <measurement group_id="O5" value="6177.45" spread="1977.067"/>
                    <measurement group_id="O6" value="12068.75" spread="10609.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Oral Clearance of MLN3126</title>
        <description>CL/F is apparent clearance of the drug from the plasma, after extravascular administration.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Oral Clearance of MLN3126</title>
          <description>CL/F is apparent clearance of the drug from the plasma, after extravascular administration.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="1.457"/>
                    <measurement group_id="O2" value="11.34" spread="5.934"/>
                    <measurement group_id="O3" value="15.12" spread="6.345"/>
                    <measurement group_id="O4" value="13.97" spread="2.473"/>
                    <measurement group_id="O5" value="16.76" spread="6.656"/>
                    <measurement group_id="O6" value="4.23" spread="1.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T ½: Half-life of MLN3126 and Metabolite M-I</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>T ½: Half-life of MLN3126 and Metabolite M-I</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK plasma concentration.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.94" spread="0.992"/>
                    <measurement group_id="O2" value="12.80" spread="0.624"/>
                    <measurement group_id="O3" value="16.07" spread="5.899"/>
                    <measurement group_id="O4" value="16.31" spread="3.706"/>
                    <measurement group_id="O5" value="13.63" spread="1.888"/>
                    <measurement group_id="O6" value="13.92" spread="0.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" spread="1.815"/>
                    <measurement group_id="O2" value="13.47" spread="1.524"/>
                    <measurement group_id="O3" value="19.88" spread="16.767"/>
                    <measurement group_id="O4" value="20.89" spread="9.006"/>
                    <measurement group_id="O5" value="14.09" spread="3.053"/>
                    <measurement group_id="O6" value="13.56" spread="1.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae (0-96): Total Amount of MLN3126 and Metabolite M-I Excreted in the Urine</title>
        <description>Ae (0-96) is the total amount of drug excreted in urine from time 0 to time 96 hours.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae (0-96): Total Amount of MLN3126 and Metabolite M-I Excreted in the Urine</title>
          <description>Ae (0-96) is the total amount of drug excreted in urine from time 0 to time 96 hours.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65864.50" spread="13803.378"/>
                    <measurement group_id="O2" value="128194.87" spread="41264.086"/>
                    <measurement group_id="O3" value="115101.67" spread="101342.371"/>
                    <measurement group_id="O4" value="115443.11" spread="45489.137"/>
                    <measurement group_id="O5" value="179199.95" spread="94480.203"/>
                    <measurement group_id="O6" value="216883.09" spread="193535.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1606271.00" spread="661316.505"/>
                    <measurement group_id="O2" value="3785848.92" spread="1487530.534"/>
                    <measurement group_id="O3" value="3669719.92" spread="3805989.870"/>
                    <measurement group_id="O4" value="3042712.33" spread="1087430.529"/>
                    <measurement group_id="O5" value="4934093.92" spread="2367261.267"/>
                    <measurement group_id="O6" value="7969436.83" spread="9141564.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fe: Fraction of MLN3126 Excreted in the Urine</title>
        <description>Fe is the Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe: Fraction of MLN3126 Excreted in the Urine</title>
          <description>Fe is the Fraction of drug excreted in urine, calculated as Fe=(Ae[0-t]/dose)×100.</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.005"/>
                    <measurement group_id="O2" value="0.02" spread="0.007"/>
                    <measurement group_id="O3" value="0.01" spread="0.002"/>
                    <measurement group_id="O4" value="0.01" spread="0.003"/>
                    <measurement group_id="O5" value="0.01" spread="0.005"/>
                    <measurement group_id="O6" value="0.01" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) of MLN3126 and Metabolite M-I</title>
        <description>Renal clearance was calculated as CLr=Ae(0-96)/AUC (0-96).</description>
        <time_frame>Pre-dose and multiple timepoints post-dose (Up to 96 Hours)</time_frame>
        <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN3126 300 mg</title>
            <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MLN3126 600 mg</title>
            <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MLN3126 1000 mg</title>
            <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MLN3126 1500 mg</title>
            <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MLN3126 2000 mg</title>
            <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MLN3126 1000 mg (Fed)</title>
            <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of MLN3126 and Metabolite M-I</title>
          <description>Renal clearance was calculated as CLr=Ae(0-96)/AUC (0-96).</description>
          <population>PK analysis set included all participants who received study drug and who had at least 1 measurable PK urine concentration.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MLN3126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.010"/>
                    <measurement group_id="O2" value="0.04" spread="0.010"/>
                    <measurement group_id="O3" value="0.02" spread="0.010"/>
                    <measurement group_id="O4" value="0.02" spread="0.010"/>
                    <measurement group_id="O5" value="0.02" spread="0.012"/>
                    <measurement group_id="O6" value="0.01" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLN3126 M-I Metabolite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" spread="9.945"/>
                    <measurement group_id="O2" value="16.15" spread="3.426"/>
                    <measurement group_id="O3" value="10.34" spread="7.285"/>
                    <measurement group_id="O4" value="7.89" spread="2.544"/>
                    <measurement group_id="O5" value="13.69" spread="7.728"/>
                    <measurement group_id="O6" value="9.05" spread="5.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to 30 days post last dose (Up to Day 31)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MLN3126 300 mg</title>
          <description>MLN3126 300 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>MLN3126 600 mg</title>
          <description>MLN3126 600 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MLN3126 1000 mg</title>
          <description>MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MLN3126 1500 mg</title>
          <description>MLN3126 1500 mg tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MLN3126 2000 mg</title>
          <description>MLN3126 2000 mg tablets, orally, fasting once on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo-matching MLN3126 tablets, orally, fasting, once on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>MLN3126 1000 mg (Fed)</title>
          <description>MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Placebo (Fed)</title>
          <description>Placebo matching MLN3126 tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takeda Study Registration Call Center</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>medicalinformation@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

